Microvast’s Profit Turnaround Faces Margin Test as Market Bets on Execution

The core event was a clear miss. For the fourth quarter of 2025, Microvast reported an earnings per share of -$0.11, far below the analyst consensus of $0.03. Revenue came in at $96.4 million, also missing the projected $133.75 million. By the numbers, this was a disappointing print.

Yet the market's reaction told a different story. Despite the double miss, the stock rose 14.35% in aftermarket trading. This classic "sell the news" dynamic suggests the rally was driven by relief. The market was braced for a worse outcome, perhaps a deeper loss or a more severe revenue collapse, and the actual results were less bad than feared. The positive surprise was in the relative performance, not the absolute numbers.

Zooming out, the underlying demand picture provides context for the fragile turnaround. For the full year, revenue reached $427.5 million, representing a solid 12.6% year-over-year increase. This growth trajectory shows the core business is still expanding. The Q4 miss appears more like a quarterly volatility spike against a longer-term growth trend, rather than a fundamental breakdown.

The central question, then, is about sustainability. The rally indicates investors are looking past this quarter's disappointment to the broader profit turnaround. The company did report a significant improvement in operating profit, moving from a loss to $6.98 million for the full year. But the Q4 EPS miss, combined with a gross profit margin of 28.6% that was impacted by inventory impairment, hints that the path to consistent profitability may be bumpier than the headline revenue growth suggests. The market is betting on the turnaround, but the expectation gap remains wide.

The Profit Turnaround: Quality and the Margin Trap

The headline "profit turnaround" is real, but it requires careful unpacking. For the full year 2025, Microvast reported an operating profit of $6.98 million, a dramatic swing from an operating loss of $116.1 million the prior year. This is a clear sign of improving operational leverage. The company also generated a substantial $75.9 million in operating cash flow, a key indicator of underlying business health that far exceeds the bottom-line profit figure.

Yet the margin story reveals a critical trap. The company's gross margin fell to 28.6% for the year, down from 31.5%. This decline was not due to pricing pressure or inefficiency, but a one-time accounting charge: a $32.5 million inventory impairment that cut the margin by about 7.6 percentage points. Management noted that underlying gross margin reflected a more favorable product mix and improved manufacturing efficiencies when excluding this non-cash charge. In other words, the core business was actually performing better on a per-unit basis, but the impairment distorted the headline number.

This creates a classic expectation gap. The market is pricing in a genuine operational improvement, evidenced by the positive operating profit and strong cash flow. However, the margin trap reminds investors that the path to sustainable profitability is not just about scaling revenue. It involves navigating inventory management and absorbing non-recurring charges. The profit turnaround is more about expense control and cash generation than it is about gross margin expansion in the near term. For the turnaround to be credible, the company must now demonstrate that it can protect its margins as it ramps production, like the new Huzhou Phase 3.2 facility.

The 2026 Expectation Gap: Capacity, Customers, and Headwinds

The market's post-earnings rally priced in a profit turnaround, but the real test is the path to sustained profitability in 2026. Management's stated focus is on achieving serial production at its Huzhou expansion and launching a new 55Ah cell. This is the execution phase where the company must convert its record revenue growth into reliable, high-margin output. The stock's current level near $1.45 implies significant skepticism about that path. At this price, investors are not betting on a smooth ramp; they are pricing in the risks of delays and margin pressure.

A key headwind is regulatory instability, specifically cited for the evolving regulatory changes in South Korea. This is not a minor friction point. It directly impacts a region where the company is building capacity and where customer ramp-up delays have already been noted. This regulatory overhang highlights the execution risk that the market is weighing against the promised operational leverage. Scaling production in a volatile policy environment is a tougher challenge than simply building a factory.

The forward view, then, is a classic expectation gap. The market has priced in the turnaround based on improved operating profit and cash flow. Now, it must price in the next set of catalysts: the successful serial production of the Huzhou Phase 3.2 expansion and the commercial launch of the new 55Ah cell. These are the steps that will determine if the company can protect its margins and diversify its customer base as promised. Until those milestones are hit, the stock's low valuation suggests the market remains unconvinced that the profit turnaround is durable. The setup is clear: the company must deliver flawless execution to close the gap between its promising fundamentals and its deeply skeptical stock price.

Catalysts and Risks: What to Watch for the Next Re-rating

The market's post-earnings rally priced in a profit turnaround, but the next leg higher depends on a series of near-term catalysts. The stock's current low valuation suggests investors are waiting for proof that the company can execute its manufacturing ramp without sacrificing the hard-won margin improvement. The next critical test arrives on May 11, 2026, with the company's next earnings call. This will be a make-or-break moment to see if management can guide to sequential improvement, moving the narrative from "profitable" to "profitably growing."

The specific milestones to watch are the tangible signs of a manufacturing ramp. Progress on the Huzhou phase 3.2 expansion and the commercial launch of the new 55Ah cell are the key indicators that the company is scaling its high-value production. Success here would validate the path to higher-margin output and diversify the customer base as promised. Any delay or setback would reinforce the market's skepticism about the durability of the turnaround.

The paramount risk, however, is margin compression. The company must protect its 28.6% gross margin without further impairments. The 2025 decline was a one-time hit from a $32.5 million inventory charge, but the underlying business must now demonstrate it can maintain that level as production scales. If costs creep up or another impairment is needed, it would directly undermine the core thesis of sustainable profitability. The expectation gap here is clear: the market is betting on operational leverage, but it will demand evidence that the company can protect its pricing power and efficiency.

For the stock to re-rate meaningfully, Microvast must bridge these catalysts and risks. The May earnings call is the first formal checkpoint. Investors should listen for concrete updates on the Huzhou ramp and the 55Ah launch timeline, coupled with a commitment to margin protection. Meeting these near-term execution targets is the only path to convincing the market that the profit turnaround is real and durable, not just a one-quarter relief rally.